An Open-label Phase 2 Study of Dalantercept in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Dalantercept (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Acceleron Pharma
- 20 Sep 2016 Primary endpoint (Objective response rate) has not been met according to the results published in the Cancer.
- 20 Sep 2016 Results published in the Cancer
- 21 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.